CRISPR and Cas Genes Market Size

CRISPR & Cas Genes Market size was over USD 5.09 billion in 2025 and is projected to reach USD 23.44 billion by 2035, growing at around 16.5% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of CRISPR & cas genes is assessed at USD 5.85 billion.

Heightening incidences of genetic disorders and abnormal mutation worldwide are pushing biotech pioneers to engage their resources in the CRISPR & cas genes market to draft a more personalized approach to cure. Over 7000 types of genetic conditions were identified around the globe, where the occurrence of a single type ranged between 3.5% and 5.9%: 2022 Genetics in Medicine Journal. Another 2020 NLM article predicted that the genetic prevalence of autosomal recessive (AR) inherited retinal diseases (IRDs) was affecting 5.5 million habitats globally. Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) has become a revolutionary method to produce such targeted therapies to combat the widespread.

Further, the contribution of the CRISPR & cas genes market in reducing production costs and enhancing the efficacy of cell-based therapeutics is attracting investors. The cost per patient may vary as per the target, application, and development process of the genomic therapies. As per an NLM report, published in November 2023, the prior batch of these offerings was priced up to USD 3.5 million (for individual treatment). It also put an example of sickle cell disease (SCD) therapy, costing each patient USD 1.0 million. It signifies the growing need for extensive capital influx and government support to make them more accessible and affordable for widespread use. Thus, the genome industry is now encouraging innovations in this field to mitigate the high payers’ pricing tag from associated therapies.

Payers’ Pricing of Selected FDA-approved Genomic Therapies

Source: 2022 NLM Report